glycine has been researched along with Lymphoma, Mantle-Cell in 2 studies
Lymphoma, Mantle-Cell: A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Since 2003, the US Food and Drug Administration approval of bortezomib, a proteasome inhibitor, has changed the management of hematologic malignancies and dramatically improved outcomes for patients with multiple myeloma and mantle cell lymphoma." | 4.95 | Proteasome inhibitors: structure and function. ( Annunziata, CM; Nunes, AT, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nunes, AT | 1 |
| Annunziata, CM | 1 |
| Prasad, A | 1 |
| Park, IW | 1 |
| Allen, H | 1 |
| Zhang, X | 1 |
| Reddy, MV | 1 |
| Boominathan, R | 1 |
| Reddy, EP | 1 |
| Groopman, JE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 1, Dose Escalation Study To Assess the Safety, Pharmacokinetics and Activity of 2-Hour Continuous Intravenous Dosing of ON 013105 Administered Weekly in Patients With Relapsed/Refractory Lymphoma and Acute Lymphoid Leukemia[NCT01049113] | Phase 1 | 7 participants (Actual) | Interventional | 2009-11-30 | Terminated (stopped due to Lack of available clinical drug supply) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for glycine and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
Proteasome inhibitors: structure and function.
Topics: Antineoplastic Agents; Boron Compounds; Bortezomib; Glycine; Hematologic Neoplasms; Humans; Lymphoma | 2017 |
1 other study available for glycine and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cyclin D1; Eukaryotic Initiation Factor-4E; Extr | 2009 |